Inhibitors of leukotriene A4 hydrolase
This present disclosure is directed to compounds of formula (I): where R 1a , R 3 , Y, and Z are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A 4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions including the compounds described herein and methods of preparing the compounds described herein are also provided.
1. A compound having the following formula (I-A):
wherein
R 1a is hydrogen, halo, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, cyano, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted amidinyl, optionally substituted guanidinyl, —R 13 —OR 10 , —R 13 —C(═O)OR 10 , or —R 13 —C(═O)R 10 ;
Y is hydrogen, halo, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, cyano, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cyoloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl; and
Z is
each R 10 is independently hydrogen, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl;
each R 12 is independently an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain, or an optionally substituted straight or branched alkynylene chain;
each R 13 is independently a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain, or an optionally substituted straight or branched alkynylene chain;
as a single stereoisomer or as a mixture of stereoisomers;
or a pharmaceutically acceptable salt, ammonium ion, or N-oxide thereof.
2. A compound according to claim 1 wherein R 1a is optionally substituted heteroaryl and Z is
3. A compound according to claim 1 wherein the compound is 1-(2-(4-((4-(4-(oxazol-2-yl)phenoxy)phenyl)amino)piperidin-1-yl)acetyl)piperidine-4-carboxylic acid.
4. A compound according to claim 1 selected from a formula in the Table below:
R 1a
Y
Z
H—
H—
Heteroaryl—
H—
H—
Halo—
H—
Cl—
H—
H—
H—
Heteroaryl—
H—
H—
Halo—
H—
Cl—
H—
5. A compound according to claim 1 wherein R 1a is halo and Z is
6. A compound according to claim 1 wherein R 1a is —Cl and Z is
7. A compound of claim 1 wherein R 1a is a halo and Z is
8. A compound of claim 1 wherein R 1a is —Cl and Z is
9. A compound according to claim 1 wherein R 1a is optionally substituted heteroaryl and Z is
10. A compound according to claim 1 wherein R 1a is
and Z is
11. A compound according to claim 1 wherein R 1a is
and Z is
12. A compound according to claim 1 wherein R 1a is —H and Z is
13. A compound according to claim 1 wherein R 1a is —H and Z is